Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Resectable Non-Small Cell Lung Cancer

Study identifier:D9108C00002

ClinicalTrials.gov identifier:NCT03794544

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)

Medical condition

Resectable

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab, Oleclumab, Monalizumab, Danvatirsen

Sex

All

Actual Enrollment

84

Study type

Interventional

Age

18 Years - 102 Years

Date

Study Start Date: 08 Mar 2019
Primary Completion Date: 13 Jan 2021
Study Completion Date: 13 Jan 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2022 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria